Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease

Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease

Abstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocomp...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea S Henden, Katie E Lineburg, Archana Panikkar, Arushi Mahajan, Ricky Nelles, Emma Wright, Pauline Crooks, Jyothy Raju, Laetitia Le Texier, Srividhya Swaminathan, Leone Beagley, Shannon Best, Matthew Solomon, Hilary Reddiex, Glen Kennedy, Siok‐Keen Tey, Michelle A Neller, Rajiv Khanna, Corey Smith
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical & Translational Immunology
Subjects:
COVID‐19
immunocompromised
SARS‐CoV‐2
VST therapy
Online Access:https://doi.org/10.1002/cti2.70038
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cti2.70038

Similar Items